secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001213900-25-050327
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex adds four OSA experts to IHL-42X advisory board; Phase 2 data July 2025
--------------------------------------------------------------------------------

- Appointed Scott Sands, Ali Azarbarzin, Lora McGill, and Nancy Collop to the IHL-42X Clinical Advisory Board.
- Company expects to announce IHL-42X Phase 2 topline data in July 2025.
- Phase 3 US study planned to start later in 2025.
- IHL-42X is an oral once-daily treatment for obstructive sleep apnea (OSA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/0001213900-25-050327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/ea0244374-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-050327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer